SNS: Sacral Nerve Stimulation for Faecal Incontinence - Placebo or Clinical Effective

Sponsor
University of Aarhus (Other)
Overall Status
Unknown status
CT.gov ID
NCT03261622
Collaborator
University of Tromso (Other), Hvidovre University Hospital (Other)
75
1
2
48
1.6

Study Details

Study Description

Brief Summary

Sacral nerve stimulation (SNS) has over the last 20 years been recognised as an efficient treatment option for faecal incontinence (FI).

In a selected patient group we have evidence that 90% of patients will have a successful test period (≥50% reduction in incontinence episodes). If preoperative there is motor response on at least 3 out of 4 poles on the lead, at a threshold ≤1.5 mAMP.

Hypotheses In a selected patient group suffering from faecal incontinence a one-stage permanent implant will be possible. The functional results will be improved as more time can be spent finding the optimal pacemaker settings as the risk of infection is reduced compared to the stage implant. One-Stage implantation gives the opportunity to test the amount of placebo effect with SNS.

During the first 3 months postoperative patients will be randomized to either stimulation amplitude set at 90% of sensory threshold (control group) or 3 periods of stimulation at 0.05v (placebo), 50% and 90% of sensory threshold. Patients are randomized in a 1 to 2 pattern. After the initial 3 months the stimulation amplitude is increased to sensory threshold. After six months the project ends and the number of patients achieving the 50% improvement in incontinence episodes are evaluated.

Condition or Disease Intervention/Treatment Phase
  • Device: Sacral nerve stimulation at different stimulation amplitudes
N/A

Detailed Description

Sacral nerve stimulation (SNS) has over the last 20 years been recognised as an efficient treatment option for faecal incontinence (FI). The therapy is recommended by the International Continence Society (ICS) if conservative treatments such as; regulation of diet and fibre supplements, medication, biofeedback therapy, glycerol suppositories, mini enema or transanal irrigation have been insufficient to improve continence to a satisfactory level.

The SNS therapy has traditionally been applied as a two step procedure. Firstly, a 3-4 week test-period, often with a permanent electrode with tines, followed by permanent implantation if at least a 50% symptom reduction has been obtained during the test stimulation.

In a selected patient group(idiopathic faecal incontinence or incontinence as a result of an external anal sphincter tear (<160 degrees)) we have evidence that 90% of patients will have a successful test period (≥50% reduction in incontinence episodes). If preoperative there is motor response on at least 3 out of 4 poles on the lead, at a threshold ≤1.5 mAMP(unpublished data, submitted for publication) .

Thus, only 10% of the patients have the lead explanted after 3 to 4 weeks. In 90% of the patients a pacemaker is implanted after the test period, these patients will have an additional operation that could have been avoided if they had the permanent pacemaker implanted at the first stage.

Hypotheses In a selected patient group suffering from faecal incontinence a one-stage permanent implant will be possible. The functional results will be improved as more time can be spent finding the optimal pacemaker settings as the risk of infection is reduced compared to the stage implant. One-Stage implantation gives the opportunity to test the amount of placebo effect with SNS.

During the first 3 months postoperative patients will be randomized to either stimulation amplitude set at 90% of sensory threshold (control group) or 3 periods of stimulation at 0.05v (placebo), 50% and 90% of sensory threshold. Patients are randomized in a 1 to 2 pattern. After the initial 3 months the stimulation amplitude is increased to sensory threshold. After six months the project ends and the number of patients achieving the 50% improvement in incontinence episodes are evaluated.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients will be randomized to either control group (Stimulation amplitude at 90% of sensory threshold) or intervention arm (different stimulation amplitude - 0.05 V, 50 and 90% of sensory threshold)Patients will be randomized to either control group (Stimulation amplitude at 90% of sensory threshold) or intervention arm (different stimulation amplitude - 0.05 V, 50 and 90% of sensory threshold)
Masking:
Double (Participant, Investigator)
Masking Description:
Alle patients are stimulated sub-sensory in (3x4 weeks) and will be blinded. The investigators will not participate in the randomization, and setting of the stimulation amplitude.
Primary Purpose:
Basic Science
Official Title:
Sacral Nerve Stimulation for Faecal Incontinence - Placebo or Clinical Effective: A Randomized Blinded Study
Actual Study Start Date :
Nov 1, 2016
Anticipated Primary Completion Date :
Nov 1, 2019
Anticipated Study Completion Date :
Nov 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control arm

Stimulation amplitude at 90% of sensory threshold during period 1 to 3. (each period 4 weeks)

Device: Sacral nerve stimulation at different stimulation amplitudes
Exploring the effect of different stimulation amplitude in a randomized study

Sham Comparator: Intervention arm

Alternation of stimulation amplitude Period - Stimulation amplitude 0.05 Volts (lowest possible) Period - Stimulation amplitude - 50% of sensory threshold. Period - Stimulation amplitude - 90% of sensory threshold.

Device: Sacral nerve stimulation at different stimulation amplitudes
Exploring the effect of different stimulation amplitude in a randomized study

Outcome Measures

Primary Outcome Measures

  1. Bowel Habit Diary changes [12 weeks]

    Change in number of incontinence episodes(Bowel Habit diary - ≥50% reduction in fecal incontinence episodes), compared to baseline.

  2. Bowel Habit Diary changes [4 weeks]

    Change in number of incontinence episodes(Bowel Habit diary - ≥50% reduction in fecal incontinence episodes), compared to baseline.

Secondary Outcome Measures

  1. Bowel Habit Diary [24 weeks]

    Change in number of incontinence episodes(Bowel Habit diary - ≥50% reduction in fecal incontinence episodes), compared to baseline.

  2. Functional outcome measure - Wexner Incontinence score [4, 8, 12, and 24 weeks]

    Changes in Wexner incontinence score, compared to baseline.

  3. Functional outcome measure - St. Marks incontinence score [4, 8, 12, and 24 weeks]

    Changes in St. Marks incontinence score, compared to baseline.

  4. Quality of Life FI - specific [4, 8, 12, and 24 weeks]

    Changes in Rockwood Faecal Incontinence Quality of Life score, compared to baseline

  5. Changes in functional outcome - Urin incontinence (UI). [4, 8, 12, and 24 weeks]

    ICIQ_UI Short form,

  6. Visual analogue score (VAS score): patients overall satisfaction [4, 8, 12, and 24 weeks]

    VAS-score (0-100) for patients satisfaction with overall: Social function Bowel function Quality of life Baseline value used as reference

  7. Anal physiology test [baseline, 4,8,12 and 25 weeks after implantation(Only in patients implanted in Aarhus, Denmark)]

    Functional Lumen Imaging Probe (endoFLIP) and anal sensibility. The endoFLIP allows dynamic examination of the geometry and segmental distensibility properties of the anal canal by simultaneous measurement of anal pressure(PSI) and luminal cross sectional areas (CSAs) at 16 points along the length of the anal canal

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ≥18 years

  • Informed consent

  • Idiopathic faecal incontinence or incontinence following external sphincter tear ≤ 160 degrees.

  • ≥ one faecal incontinence episode after optimized conservative treatment.

  • Ability to use the patient programmer.

Exclusion Criteria:
  • Pregnancy

  • Diabetes

  • Neurological diseases, including spinal cord injuries

  • Pelvic irradiation

  • Rectal resections

Contacts and Locations

Locations

Site City State Country Postal Code
1 Anal Physiology Laboratory, Surgical Research Section 900, Aarhus University Hospital Aarhus Aarhus C Denmark 8000

Sponsors and Collaborators

  • University of Aarhus
  • University of Tromso
  • Hvidovre University Hospital

Investigators

  • Principal Investigator: Jakob K. Jakobsen, MD. Ph.D., Anal Physiology Laboratory, Surgical Research Section 900, Aarhus University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jakob Jakobsen, Principal Investigator (M.D. Ph.D.), University of Aarhus
ClinicalTrials.gov Identifier:
NCT03261622
Other Study ID Numbers:
  • 005
First Posted:
Aug 25, 2017
Last Update Posted:
Aug 25, 2017
Last Verified:
Aug 1, 2017
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jakob Jakobsen, Principal Investigator (M.D. Ph.D.), University of Aarhus
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 25, 2017